|Table of Contents|

Docetaxel Down-Regulation of Smad3 Expression in Prostate CancerCell Lines Independent of TGF-β1 Signaling(PDF)

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

Issue:
2016年03期
Page:
89-
Research Field:
·生命科学·
Publishing date:

Info

Title:
Docetaxel Down-Regulation of Smad3 Expression in Prostate CancerCell Lines Independent of TGF-β1 Signaling
Author(s):
Pi Yurui; Li Tonghui; Chen Xiubin; Liu Ping; Lu Shan
School of Life Sciences，Nanjing Normal University，Jiangsu Key Laboratory for Molecular and Medical Biotechnology，Nanjing 210023，China
Keywords:
docetaxel; Smad3; prostate cancer; down-regulation
PACS:
Q28
DOI:
10.3969/j.issn.1001-4616.2016.03.015
Abstract:
As a taxane anticancer drug，docetaxel（DOC）derived from the European yew needles has been widely used as the therapies for multiple cancers in clinic though a lot of related mechanism remains unclear. In this study，the DOC regulation of Smad3 expression in the presence of TGF-b signal was first observed in prostate cancer cell line PC-3 level，and then the effects of DOC on cell growth and Smad3 expression in the absence of TGF-b1 signal was investigated in prostate cancer LNCaP cells without TGF-b RII to explore related mechanism mainly by reverse transcription polymerase chain reaction（RT-PCR），Western blot，etc. It was found that DOC not only down-regulated Smad3 mRNA and protein levels in PC-3 cells in a time-and dose-dependent ways，but also selectively reduced Smad3 expression and inhibited cell growth in LNCaP cells while Smad2 expression was not decreased，and DOC also reduced Smad3 expression in PC-3 cells cultured in the absence of TGF-b1. Meanwhile，the Stat1 expressions in both of PC-3 and LNCaP cells were significantly inhibited by DOC. Moreover，Stat1 and Smad3 could bind together to form complex. Besides，it is also speculated that 5 potential binding sites for Stat1 existed from the analysis for Smad3 core promoter region. In total，DOC down-regulation of Smad3 is not depend on the TGF-b1 signaling，and may be caused by affecting Stat1 bindings with Smad3 promoter specific sites.

References:

［1］ JAIN A，THAKUR K，KUSH P，et al. Docetaxel loaded chitosan nanoparticles：formulation，characterization and cytotoxicity studies［J］. Int J Biol Macromol，2014，69：546-53.
［2］ KOPCZYNSKA E. Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel［J］. Contemp Oncol（Pozn），2016，19（6）：423-427.
［3］ HORWITZ S B. Mechanism of action of taxol［J］. Trends Pharmacol Sci，1992，13（4）：134-136.
［4］ HIROSE A，TAJIMA H，OHTA T，et al. Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line［J］. Oncol Lett，2013，6（4）：915-920.
［5］ TSUKADA T，FUSHIDA S，HARADA S，et al. Low-dose paclitaxel modulates tumour fibrosis in gastric cancer［J］. Int J Oncol，2013，42（4）：1 167-1 174.
［6］ WANG C，SONG X，LI Y，et al. Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation［J］. PLoS One，2013，8（8）：e70725.
［7］ YAO B，ZHAO J，LI Y，et al. Elf5 inhibits TGF-beta-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation［J］. Prostate，2015，75（8）：872-82.
［8］ 刁小伟，李园，皮玉瑞，等. 雄激素依赖性前列腺癌细胞中雄激素受体上调EphA3表达［J］. 天津医药，2015，43（11）：1?253-1 257.
［9］ 董源，汤灵玲，林林，等. 蛋白含量检测的抗干扰新方法［J］. 生物工程学报，2012，28（9）：1 130-1 138.
［10］ AREF-ESHGHI E，LIU M，RAZAVI-LOPEZ S B，et al. SMAD3 is upregulated in human osteoarthritic cartilage independent of the promoter DNA methylation［J］. J Rheumatol，2016，43（2）：388-394.
［11］ LEE J Y，ELMER H L，ROSS K R，et al. Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells［J］. Am J Respir Cell Mol Biol，2004，31（2）：234-240.
［12］ CENGIZ E，KARACA B，KUCUKZEYBEK Y，et al. Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line，PC-3 by docetaxel and gossypol combination［J］. Mol Biol Rep，2010，37（3）：1 269-1 277.
［13］ MOHR A，CHATAIN N，DOMOSZLAI T，et al. Dynamics and non-canonical aspects of JAK/STAT signalling［J］. Eur J Cell Biol，2012，91（6/7）：524-532.
［14］ YANG Q，WANG Y，LU X，et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells［J］. Oncotarget，2015，6（5）：3 268-3 279.
［15］ ZHANG Y，HUANG S. Up-regulation of miR-125b reverses epithelial-mesenchymal transition in paclitaxel-resistant lung cancer cells［J］. J Biol Chem，2015，15（4）：45.
［16］ ADAMKPVA L，SOUCKOVA K，KOVARIK J，et al. Transcription protein STAT1：biology and relation to cancer［J］. Folia Biol（Praha），2007，53（1）：1-6.
［17］ RAVEN J F，WILLIAMS V，WANG S，et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation［J］. Cell cycle，2011，10（5）：794-804.
［18］ KHARMA B，BABA T，MATSUMURA N，et al. STAT1 drives tumor progression in serous papillary endometrial cancer［J］. Cancer Res，2014，74（22）：6 519-6 530.
［19］ ARZT L，KOTHMAIER H，HALBWEDL I，et al. Signal transducer and activator of transcription 1（STAT1）acts like an oncogene in malignant pleural mesothelioma［J］. Virchows Arch，2014，465（1）：79-88.
［20］ ZHANG M. Novel function of STAT1 in breast cancer［J］. Oncoimmunology，2013，2（8）：e25125.
［21］ PATTERSON S G，WEI S，CHEN X，et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells［J］. Oncogene，2006，25（45）：6 113-6 122.

Memo

Memo:
-
Last Update: 2016-09-30